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ORIGINAL ARTICLE BACTERIOLOGYTranscriptomic analysis of colistin-susceptible and colistin-resistant
isolates identiﬁes genes associated with colistin resistance in Acinetobacter
baumanniiY. K. Park, J.-Y. Lee and K. S. Ko
Department of Molecular Cell Biology, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, KoreaAbstractThe emergence of colistin-resistant Acinetobacter baumannii is concerning, as colistin is often regarded as the last option for treating multidrug-
resistant (MDR) A. baumannii infections. Using mRNA sequencing, we compared whole transcriptomes of colistin-susceptible and colistin-
resistant A. baumannii strains, with the aim of identifying genes involved in colistin resistance. A clinical colistin-susceptible strain (06AC-
179) and a colistin-resistant strain (07AC-052) were analysed in this study. In addition, a colistin-resistant mutant (06AC-179-R1) derived
from 06AC-179 was also included in this study. High throughput mRNA sequencing was performed with an Illumina HiSeq TM 2000. In
total, six genes were identiﬁed as associated with colistin resistance in A. baumannii. These six genes encode PmrAB two-component
regulatory enzymes, PmrC (a lipid A phosphoethanolamine transferase), a glycosyltransferase, a poly-β-1,6-N-acetylglucosamine
deacetylase, and a putative membrane protein. Matrix-assisted laser desorption/ionization time of ﬂight mass spectrometry revealed that
all three colistin-resistant strains used in this study had modiﬁed lipid A structure by addition of phosphoethanolamine. As genes found in
our results are all associated with either lipopolysaccharide biosynthesis or electrostatic changes in the bacterial cell membrane,
lipopolysaccharide modiﬁcation might be one of the principal modes of acquisition of colistin resistance in some A. baumannii strains.
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Centre for Disease Control and Prevention, Cheongju, KoreaIntroductionAcinetobacter baumannii is one of the most important oppor-
tunistic pathogens, and is responsible for diverse nosocomial
infections including bacteraemia, urinary tract infections and
pneumonia [1]. Polymyxins, including colistin, have traditionallyClinical Microbiology and Infection © 2015 European Society of Cnot been used because of their neurotoxicity and nephrotoxi-
city; however, colistin is now considered the last option against
multidrug-resistant Acinetobacter infections [2,3]. Although the
current resistance rates to colistin are relatively low, they are
increasing and become a serious problem worldwide [4].
In other Gram-negative bacteria, such as Pseudomonas aeru-
ginosa and Salmonella enterica, colistin resistance is known to
involve lipopolysaccharide (LPS) modiﬁcation by the addition of
4-amino-L-arabinose or phosphoethanolamine. Furthermore,
the PmrAB and PhoPQ two-component regulatory systems
have been reported to mediate LPS modiﬁcation in those
species [5,6]. In A. baumannii, elevated expression of pmrAB
genes related to colistin resistance has been reported [7,8].
Furthermore, mutations in the lpxACD genes have been shown
to confer colistin resistance to A. baumannii, due to the loss of
LPS. However, these are not the only explanations for colistinClin Microbiol Infect 2015; 21: 765.e1–765.e7
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.cmi.2015.04.009
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elevated pmrAB gene expression and lacking mutations in the
lpxACD genes have also been identiﬁed [8]. Hence, additional
mechanisms may be associated with colistin resistance in
A. baumannii.
In this study, we used mRNA sequencing to compare whole
transcriptomes of colistin-resistant and colistin-susceptible
A. baumannii strains, with the aim of identifying genes associ-
ated with colistin resistance.Materials and methodsBacterial isolates and growth conditions and
antimicrobial susceptibility testing
One colistin-susceptible (06AC-179) and two colistin-resistant
(07AC-052 and 07AC-111) A. baumannii strains, obtained from
the Samsung Medical Centre (Seoul, Korea), were used in this
study. In addition, a colistin-resistant mutant (06AC-179-R1)
was derived in vitro from a colistin-susceptible strain, 06AC-179
(Table 1) [8]. Escherichia coli DH5α cells were used for cloning.
Selection and maintenance of transformants was achieved with
50 mg/L ampicillin and 50 mg/L gentamicin for E. coli, and
100 mg/L kanamycin and 50 mg/L gentamicin for A. baumannii.
The MICs of polymyxins and other six antimicrobial agents
were determined by the broth microdilution method according
to the CLSI guidelines [9].
Messenger RNA sequencing
Total RNA was extracted from two clinical strains and one
mutant strain of A. baumannii (06AC-179, 07AC-052 and
06AC-179-R1), using the Qiagen RNeasy Mini Kit (Qiagen,
Valencia, CA, USA). Overnight cultures were inoculated 1 : 100
in Luria–Bertani (LB) broth without colistin and grown until
mid-log phase (optical density at 600 nm 0.5) at 37°C with
shaking (180 rpm) for total RNA extraction. Isolated RNA was
sent to Macrogen Inc. (Seoul, Korea) for further procedures.
After isolation of RNA, cDNA was synthesized and sequencing
libraries were generated in a strand-speciﬁc manner accordingTABLE 1. Summary for mRNA sequencing and resistance proﬁles o
resistance-induced mutant
Strain Source
mRNA sequencing Antimicrob
Total read Mapped read (%) CL
06AC-179 Blood 21 214 868 19 117 733 (90.11) 1 (S)
06AC-179-R1 — 15 987 058 14 377 187 (89.93) >64 (R)
07AC-052 Tracheal aspirate 11 799 114 10 272 850 (87.06) >64 (R)
07AC-111 Tracheal aspirate — — 16 (R)
aCL, colistin; PB, polymyxin B; IMP, imipenem; CPM, cefepime; AMK, amikacin; CIP, ciproﬂo
susceptible.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectto the Illumina standard protocol for high-throughput
sequencing. Library sequencing was carried out with the Illu-
mina HiSeq TM 2000 sequencer; the SOLEXAQA program was
used to verify sequence quality. Expression levels of mRNA are
expressed as reads per kilobase per million sequenced reads.
The complete genome sequence of A. baumannii ACICU (NCBI
reference sequence: NC_010611.1) was used for aligning reads.
Quantitative real-time PCR
Genes showing a more than ﬁve-fold difference in expression
level in both colistin-resistant strains and mutant strains
compared with the colistin-susceptible strain were validated by
quantitative real-time PCR (qRT-PCR) with standard curve
method. Transcripts were quantiﬁed by qRT-PCR using SYBR
Premix Ex Tag (TaKaRa, Kyoto, Japan) and a Thermal Cycler
Dice Real Time System thermocycler (TaKaRa). Expression
levels of targeted genes were normalized to rpoB expression
levels. Primer sets used in this study are listed in the Supple-
mentary material (Table S1). In pmrAB-deleted (Δ03002-3::Km)
and its complemented mutants (Δ03002-3::Km+pJN105/03002-
3), expressions of nine genes validated to be associated with
colistin resistance were determined by the ΔΔCt method to
compare with the expression level of 07AC-111 parental strain.
Experiments were repeated with two independent cultures,
each tested in duplicate.
Allelic replacement mutagenesis
Genes validated by qRT-PCR were deleted by allelic replace-
ment mutagenesis as previously described with some modiﬁ-
cations [10]. We used a clinical colistin-resistant strain that was
susceptible to other antibiotics, 07AC-111 (Table 1), for
knockout and complementation experiments. We chose this
strain because the two colistin-resistant strains used for mRNA
sequencing are highly resistant to most known antibiotics;
therefore, no appropriate antibiotic markers were available for
selection. The linear fused products produced by the two-step
PCR were cloned into pUC18, which can be used as a suicide
vector in A. baumannii. Recombinant plasmids were introduced
into the 07AC-111 strain by electroporation. Selection off three clinical Acinetobacter baumannii strains and one colistin
ial susceptibility (MIC, mg/L) a
PB IMP CPM AMK CIP P/T TIG
2 (S) >64 (R) >64 (R) >128 (R) >64 (R) >256/4 (R) 2 (S)
64 (R) >64 (R) >64 (R) >128 (R) >64 (R) >256/4 (R) 2 (S)
32 (R) >64 (R) >64 (R) >128 (R) >64 (R) >256/4 (R) 4 (I)
4 (R) 0.5 (S) 2 (S) 4 (S) 0.5 (S) >1/4 (S) 0.125 (S)
xacin; P/T, piperacillin/tazobatam; TIG, tigecycline. R, resistant; I, intermediate; S,
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 765.e1–765.e7
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plates. Transformants were conﬁrmed by PCR and sequencing
for detecting modiﬁed size of genes.
Complementation experiments
To complement deletion mutants, the appropriate genes were
ampliﬁed from genomic DNA from the 07AC-111 strain with
forward and reverse primers containing PstI and SacI recogni-
tion sites at their 50 ends, respectively (see Supplementary
material, Table S1). The digested fragments of each gene were
subcloned into the broad-host-range expression vector,
pJN105, and introduced into the E. coli DH5α strain [11]. Re-
combinant pJN105 plasmids, isolated from DH5α cells, were
introduced into each knockout mutant by electroporation.
Transformants were selected on 0.5% arabinose-containing and
50 mg/L gentamicin-containing medium and conﬁrmed by PCR.
Survival analysis
The survival rates of deletion and complementation mutants
were evaluated in the presence of colistin. A parental strain
(07AC-111), deletion mutants and complementation mutants
were each grown overnight. Bacterial cells were re-inoculated
to 106 CFU/mL in LB broth containing 0.5% arabinose, and
incubated at 37°C for 30 min to induce the expression of genes
cloned into the pJN105 vector. Cultures were grown for an
additional 30 min, either with or without the presence of
colistin in the medium (10 mg/L), and subsequently plated onto
LB agar for colony counting. Survival rates were determined as
the percentages of viable cells in LB medium containing colistin
compared with viable cells in LB medium in the absence of
colistin. Experiments were repeated with three independent
cultures. Statistical analyses were performed with Student’s t
test using SPSS software. Differences were considered signiﬁ-
cant when p < 0.05.
Matrix-assisted laser desorption/ionization time of
ﬂight mass spectrometry (MALDI-TOF MS) analysis
Lipid A was isolated from A. baumannii isolates by an ammo-
nium hydroxide– isobutyric acid-based method [12]. Overnight
cultures were washed twice with water and resuspended in
400 μL of isobutyric acid and 1 M ammonium hydroxide (5 : 3,
vol/vol). Samples were heated at 100°C for 2 h and cooled in
ice for 20 min. After centrifugation for 15 min at 2000 g, su-
pernatants were diluted with endotoxin-free water (1 : 1, vol/
vol) and lyophilized. The lyophilized samples were washed
twice with 1 mL of methanol. The insoluble lipid A was
extracted in 200 μL of a mixture of chloroform, methanol and
water (3 : 1.5 : 0.25, vol/vol). Extracted lipid A was analysed by
using Ultraﬂex III TOF/TOF mass spectrometer (Bruker Dal-
tonics, Leipzig, Germany). 2,5-Dihydroxybenzoic acid (DHB)Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inwas used as the matrix; 2 μl of lipid A samples was mixed with
an equal volume of DHB dissolved in water and acetonitrile (1 :
4, vol/vol) directly on the MALDI target and vacuum drying.
Data were analysed in negative reﬂectron mode with a 100-Hz
laser repetition rate. Three hundred shots were accumulated
for each spectrum.ResultsThe three strains (06AC-179, 06AC-179-R1 and 07AC-052)
used for mRNA sequencing differed only in their susceptibilities
to polymyxins and tigecycline (Table 1). Illumina high-
throughput mRNA sequencing generated totals of
21 214 868, 15 987 058 and 11 799 114 reads and 19 117 733
(90.11%), 14 377 187 (89.93%) and 10 272 850 (87.06%) reads
were mapped from 06AC-179, 06AC-179-R1 and 07AC-052,
respectively (Sequence Read Archive accession numbers,
SRR1380973, SRR1449241 and SRR1408864, respectively)
(Table 1). Overall, transcriptomic analysis revealed that 222
genes exhibited more than two-fold increases in expression in
both colistin-resistant strains compared with the colistin-
susceptible strain (see Supplementary material, Table S2).
To investigate the common genes associated with colistin
resistance in both in vitro-selected mutant and a clinical isolate,
17 genes showing more than ﬁve-fold increased expression
were selected for further studies. Validation by quantitative RT-
PCR conﬁrmed that 11 of these genes showed signiﬁcantly
increased expression in both colistin-resistant strains (Table 2).
Overall, genes showing high fold change in mRNA sequencing
were conﬁrmed by qRT-PCR. However, ACICU_01072 and
ACICU_03001 showed high fold change of over-expression in
mRNA sequencing, but they were not conﬁrmed by qRT-PCR.
Although we analysed sequences in 17 genes with more than
ﬁve-fold increased expression, we could not ﬁnd any sequence
variations between colistin-resistant and colistin-susceptible
strains.
Using the allelic replacement method, nine target genes were
deleted in 07AC-111. As PCR products encoding the upstream
and downstream regions of ACICU_01552 and ACICU_01553
could not be obtained, possibly due to sequence poly-
morphisms in our strain, these genes were excluded.
ACICU_03002 and ACICU_03003 are located closely adjacent
to one another; hence, both genes were deleted simultaneously
(07AC-111Δ03002-3).
We compared survival rates of a parental strain and the
knockout mutants in the presence of colistin. Among the eight
knockout mutants, all but two (Δ01518::Km and Δ02907::Km)
were signiﬁcantly more sensitive to colistin compared with the
parental strain (Fig. 1a). Whereas 07AC-111 exhibited afectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 765.e1–765.e7
FIG. 1. Survival rates in the presence of colistin of different Acinetobacter baumannii strains. Survival rates in the presence of colistin (10 mg/L) were
determined for (a) the 07AC-111 parental strain and eight knockout mutants, and (b) six of the knockout mutants showing signiﬁcantly decreased
survival rates, and their complemented equivalents. All experiments were performed in triplicate. *p < 0.05. The dotted line indicates the survival rate
of the parental strain, 07AC-111. Error bars represent the standard deviations of three biological repeats.
TABLE 2. Genes showed different expression levels (more than ﬁve-fold) in both an induced colistin-resistant mutant (06AC-179-
R1) and a clinical colistin-resistant strain (07AC-052) compared with a colistin-susceptible parent strain (06AC-179)
Accession no. Description COG a
Fold change (RNA-seq / qRT-PCR)
06AC-179-R1 07AC-052
ACICU_00900 b Poly-β-1,6-N-acetylglucosamine (PNAG) deacetylase G 30.54 / 59.88 6.17 / 6.12
ACICU_01072 Predicted membrane-associated, metal-dependent hydrolase R 21.83 /18.26 10.12 / 2.22
ACICU_01158 Putative membrane protein — 5.03 / 1.27 5.53 / 0.44
ACICU_01518 b Hypothetical protein — 124.75 / 136.24 31.00 / 32.64
ACICU_01552 b Hypothetical protein — 644.99 / 321.00 758.98 / 167.40
ACICU_01553 b Hypothetical protein — 47.14 / 306.63 48.41 / 160.22
ACICU_01717 Hypothetical protein — 10.64 /1.24 18.61 / 1.10
ACICU_02866 b Glycosyltransferase M 139.29 / 361.98 6.28 / 17.45
ACICU_02868 b Conserved hypothetical protein; putative membrane protein M 96.21 / 32.75 6.30 / 5.42
ACICU_02895 b Non-ribosomal peptide synthetase module Q 70.39 / 162.30 11.20 / 32.00
ACICU_02907 b Diacylglycerol kinase M 46.26 / 23.32 14.52 / 5.60
ACICU_03001 PAP2 (acid phosphatase) superfamily protein R 52.75 /1.41 9.26 / 0.46
ACICU_03002 b Signal transduction histidine kinase (PmrB) T 20.21 / 18.59 5.51 / 5.57
ACICU_03003 b Response regulator consisting of a CheY-like receiver domain and a Winged-helix
DNA-binding domain (PmrA)
T, K 24.95 / 30.06 6.27 / 6.66
ACICU_03004 b Lipid A phosphoethanolamine transferase (PmrC) R 78.65 / 13.43 14.89 / 432.2
ACICU_03426 Acetyl-CoA hydrolase C 6.33 /1.02 5.13 / 1.17
ACICU_03497 Predicted membrane protein S 13.05 /1.75 5.94 / 1.09
aC, Energy production and conversion; G, Carbohydrate transport and metabolism; K, Transcription; M, Cell wall/membrane/envelope biogenesis; Q, Secondary metabolites
biosynthesis, transport and catabolism; R, General function prediction only; S, Function unknown; T, Signal transduction mechanisms.
bGenes conﬁrmed with quantitative RT-PCR are indicated in bold type.
765.e4 Clinical Microbiology and Infection, Volume 21 Number 8, August 2015 CMIsurvival rate of 0.18% in the presence of 10 mg/L colistin, the
survival rates of six deletion mutants ranged from 0.013%
(Δ03004::Km) to 0.07% (Δ00900::Km).
Six knockout mutants, each showing increased sensitivity to
colistin, were complemented with pJN105 containing the
appropriate gene. Survival rates in the presence of 10 mg/L
colistin were restored in all complemented strains but one,
07AC-111Δ02895::Km+pJN105/02895 (Fig. 1b). In particular,
the survival rates of Δ03002-3::Km+pJN105/03002-3 and
Δ03004::Km+pJN105/03004 increased >1576-fold and >325-
fold, respectively, compared with the parental strain. ThisClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectﬁnding underscores the importance of pmrCAB genes in colistin
resistance in A. baumannii. In a pmrAB-deleted mutant (Δ03002-
3::Km), the expression of ACICU_00900, ACICU_01518,
ACICU_01552, ACICU_02866, and ACICU_03004 decreased
signiﬁcantly. In addition, their expression was restored in its
complemented mutant (Fig. 2). Although ACICU_01553 and
ACICU_02868 were over-expressed in parental isolate and
complemented mutant, the results were insigniﬁcant or
inconsistent. On the other hand, ACICU_02895 and
ACICU_02907 may not be associated with the deletion or
complementation of pmrAB.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 765.e1–765.e7
FIG. 2. Gene expressions in pmrAB-knockout and -complemented mutants by quantitative RT-PCR. Relative expressions of nine genes were
determined using ΔΔCt method. Error bars represent the standard deviations of three biological repeats.
CMI Park et al. Transcriptomic analysis of colistin-resistant A. baumannii 765.e5Antimicrobial susceptibility of knockout and complemented
mutants was evaluated. As a result, MICs of knockout and
complemented mutants were not changed for all antibiotics
tested, compared with wild-type strain 07AC-111 (Table 1).
In MALDI-TOF MS, two common peaks found in all four
isolates correspond to a hepta-acylated lipid A with two 2-
amino-2-deoxyglucose residues, two phosphates, three
12:0(3-OH), two 14:0(3-OH) and two 12:0 (m/z 1,910) and to a
tetra-acyl lipid A with three 12:0(3-OH) fatty acids and one
14:0(3-OH) fatty acid (m/z 1,404) attached to the phosphory-
lated disaccharide (Fig. 3). Three colistin-resistant isolates had a
peak at m/z 2034, which indicates an addition of phosphoe-
thanolamine (m/z 124) to the normal hepta-acylated structure.
An induced colistin-resistant strain 06AC-179-R1 showed
additional two peaks at m/z 1937 and m/z 1954 compared with
susceptible parental strain. The peak at m/z 1,937 might be bis-
phosphorylated hexa-acylated lipid A with the addition of oneFIG. 3. Mass spectrometry of lipid A extracted from four Acinetobacter bauma
06AC-179 and induced resistant mutant 06AC-179-R1. (b) Clinical colistin-r
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inresidue of phosphoethanolamine and one residue of 2-carbon
ethanolamine (m/z 85) [13]. It is considered that the peak at
m/z 1954 might be bis-phosphorylated hepta-acylated lipid A
with the removal of one phosphate group (m/z 80) and the
addition of one residue of phosphoethanolamine [14].DiscussionIn this study, we aimed to identify candidate genes responsible
for colistin resistance by comparing whole transcriptomes from
colistin-susceptible and colistin-resistant strains. Of these 17
candidate genes exhibiting more than ﬁve-fold increased
expression in both the clinical and in vitro-derived colistin-
resistant strains, 11 were validated by qRT-PCR. Through
survival analysis in the presence of colistin of deletion and
complementation mutants, this study identiﬁed a role for sixnnii strains used in this study. (a) The colistin-susceptible parental strain
esistant strains 07AC-052 and 07AC-111.
fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 765.e1–765.e7
765.e6 Clinical Microbiology and Infection, Volume 21 Number 8, August 2015 CMIgenes (ACICU_00900, ACICU_02866, ACICU_02868,
ACICU_03002, ACICU_03003 and ACICU_03004) in colistin
resistance in A. baumannii.
The involvement of ACICU_03002 to 03004 in colistin
resistance is not surprising as they are homologues of pmrBAC,
respectively [7]. Since pmrC is known to function as a phos-
phoethanolamine transferase, we determined structures of lipid
A from all isolates used in this study by MALDI-TOF MS. As
expected, all three colistin-resistant isolates including induced
resistant isolate 06AC-179-R1 were found to have the modiﬁed
lipid A by addition of phosphoethanolamine.
This study also indicates that upregulation of ACICU_02866
encoding a glycosyltransferase contributes to the colistin
resistance in A. baumannii. Glycosyltransferases involved in the
synthesis of LPS cores were shown to be signiﬁcant in colistin
resistance in A. baumannii [15,16]. Despite the increased gly-
cosyltransferase activity, an additional lipid A modiﬁcation of
LPS was not found by MALDI-TOF MS. ACICU_02868, which
consists of the same operon as ACICU_02866, was upregulated
in both the colistin-resistant isolate and the induced resistant
isolate. The deletion and complementation experiments also
revealed that ACICU_02868 may be associated with colistin
resistance. It is suggested that upregulation of the operon
ACICU_02865 to ACICU_02868 may be associated with
colistin resistance or adaptation to colistin in A. baumannii.
Regarding the association between cell membrane integrity
and colistin resistance, overexpression of ACICU_02907
encoding a diacylglycerol kinase (DAGK) is observed in colistin-
resistant strains. In E. coli, DAGK is a small integral membrane
protein [17], whose function is to recycle the population of
diacylglycerol that is generated largely as a by-product of
membrane-derived oligosaccharide biosynthesis [18]. Hence,
overproduction of DAGK may increase the integrity of the cell
membrane, so aiding colistin resistance, although more in-
vestigations would be required.
It was shown that ACICU_00900 (or pgaB), a gene encoding
a poly-β-1,6-N-acetylglucosamine (PNAG) deacetylase, may be
associated with colistin resistance in A. baumannii. PgaB has
been shown to be associated with transport of the surface
polysaccharide, PNAG [19]. In E. coli, changes in PNAG pro-
duction have been shown to inﬂuence biosynthesis of the LPS
core [20]. In addition, upregulation of PNAG transport and
increased production of PNAG were identiﬁed in a tran-
scriptomic study of an LPS-deﬁcient (i.e. colistin-resistant)
A. baumannii strain [15]. Although neither of our colistin-
resistant strains showed abnormal expression of any of the
genes related to LPS biosynthesis, overexpression of positively
charged PNAG may inhibit the action of cationic colistin on
LPS. In addition, polysaccharide deacetylase is involved with cellClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectwall modiﬁcation [21]. Much higher increased expression of
ACICU_00900 in the complemented mutants than in the
knockout mutant of pmrAB suggests that the production of
PNAG may be regulated by the PmrAB regulatory system
(Fig. 2), although further investigation is needed. In a recent
study, the extent of A. baumannii cell wall damage was shown to
correlate with the concentration of colistin treatment;
furthermore, cell wall damage was delayed and less severe in
colistin-resistant strains [22]. Hence, cell wall modiﬁcations may
inﬂuence the uptake of antibiotics, including colistin, so
resulting in antibiotic susceptibility. Hence, a glycosyltransfer-
ase, PNAG deacetylase, and other unidentiﬁed enzymes may
constitute an interaction network that inﬂuences the integrity
of the outer membrane and cell wall, resulting in the colistin
resistance in A. baumannii.
In other bacterial species such as S. enterica, Yersinia pestis and
Klebsiella pneumoniae, the PmrAB system, which mediates
expression of the pbgP operon, is regulated in concert with the
PhoPQ system, in a feed-forward loop manner [23]. As the
PhoPQ system is absent in A. baumannii, the PmrAB system may
respond alone to environmental stimuli and promote colistin
resistance. Otherwise, there may be a cross-talk between the
PmrAB system and other unknown regulators, and a different
system may be involved in colistin resistance in A. baumannii. In
addition, we found that complemented Δ03004::Km+pJN105/
03004 had a survival rate much higher than the knockout mutant.
It conﬁrms that the addition of phosphoethanolamine to lipid A
may give a great contribution in colistin resistance in A. baumannii,
because the phosphoethanolamine was directly transferred, not
mediated by the PmrAB regulatory system [24]. In this study,
although some genes associated with colistin resistance including
ACICU_00900, ACICU_01518, ACICU_01552, ACICU_02866
and ACICU_03004 may be under the transcriptional network of
PmrAB system, other genes such as ACICU_02895 and
ACICU_02907 may not be related to the PmrAB system.
In this study, we identiﬁed and validated six genes encode
PmrAB two-component regulatory enzymes, PmrC, a glyco-
syltransferase, a PNAG deacetylase, and a putative membrane
protein by transcriptomic analysis. All of these gene products
are thought to be associated with either LPS biosynthesis or
modiﬁcation of its electrostatic properties, thereby conﬁrming
that modiﬁcation of LPS is one of the principal methods for
acquiring colistin resistance. However, our cut-off for select-
ing follow-up candidates may be too stringent to identify all the
genes associated with colistin resistance; hence, additional
colistin resistance mechanisms may also exist. Importantly,
our study also shows that comparative transcriptomic analysis
is a useful approach for investigating antibiotic resistance
mechanisms.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 765.e1–765.e7
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